

NFE2L2 Antibody (S40) Blocking Peptide
Synthetic peptide
Catalog # BP7275d**Specification****NFE2L2 Antibody (S40) Blocking Peptide -
Product Information**

Primary Accession [Q16236](#)
Other Accession [NP_006155](#)

**NFE2L2 Antibody (S40) Blocking Peptide -
Additional Information**

Gene ID 4780

Other Names

Nuclear factor erythroid 2-related factor 2,
NF-E2-related factor 2, NFE2-related factor
2, HEBP1, Nuclear factor, erythroid derived
2, like 2, NFE2L2, NRF2

Target/Specificity

The synthetic peptide sequence used to
generate the antibody [AP7275d](/products/AP7275d)
was selected from the S40 region of human
NFE2L2. A 10 to 100 fold molar excess to
antibody is recommended. Precise
conditions should be optimized for a
particular assay.

Format

Peptides are lyophilized in a solid powder
format. Peptides can be reconstituted in
solution using the appropriate buffer as
needed.

Storage

Maintain refrigerated at 2-8°C for up to 6
months. For long term storage store at
-20°C.

Precautions

This product is for research use only. Not
for use in diagnostic or therapeutic
procedures.

**NFE2L2 Antibody (S40) Blocking Peptide - Protein
Information****NFE2L2 Antibody (S40) Blocking Peptide -
Background**

NFE2 (MIM 601490), NFE2L1 (MIM 163260),
and NFE2L2 comprise a family of human basic
leucine zipper (bZIP) transcription factors. They
share highly conserved regions that are
distinct from other bZIP families, such as JUN
(MIM 165160) and FOS (MIM 164810), although
remaining regions have diverged considerably
from each other (Chan et al., 1995).

**NFE2L2 Antibody (S40) Blocking Peptide -
References**

Zhao,X., Stroke 38 (12), 3280-3286
(2007)Li,M.H., J. Biol. Chem. 282 (39),
28577-28586 (2007)

Name NFE2L2

{ECO:0000303|PubMed:29018201,
ECO:0000312|HGNC:HGNC:7782}

Function

Transcription factor that plays a key role in the response to oxidative stress: binds to antioxidant response (ARE) elements present in the promoter region of many cytoprotective genes, such as phase 2 detoxifying enzymes, and promotes their expression, thereby neutralizing reactive electrophiles (PubMed:11035812, PubMed:19489739, PubMed:29018201, PubMed:31398338). In normal conditions, ubiquitinated and degraded in the cytoplasm by the BCR(KEAP1) complex (PubMed:11035812, PubMed:15601839, PubMed:29018201). In response to oxidative stress, electrophile metabolites inhibit activity of the BCR(KEAP1) complex, promoting nuclear accumulation of NFE2L2/NRF2, heterodimerization with one of the small Maf proteins and binding to ARE elements of cytoprotective target genes (PubMed:19489739, PubMed:29590092). The NFE2L2/NRF2 pathway is also activated in response to selective autophagy: autophagy promotes interaction between KEAP1 and SQSTM1/p62 and subsequent inactivation of the BCR(KEAP1) complex, leading to NFE2L2/NRF2 nuclear accumulation and expression of cytoprotective genes (PubMed:20452972). May also

be involved in the transcriptional activation of genes of the beta-globin cluster by mediating enhancer activity of hypersensitive site 2 of the beta-globin locus control region (PubMed:7937919).

Cellular Location

Cytoplasm, cytosol. Nucleus
{ECO:0000255|PROSITE-ProRule:PRU00978,
ECO:0000269|PubMed:11035812,
ECO:0000269|PubMed:15601839,
ECO:0000269|PubMed:21196497}

Note=Cytosolic under unstressed conditions: ubiquitinated and degraded by the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:15601839, PubMed:21196497).

Translocates into the nucleus upon induction by electrophilic agents that inactivate the BCR(KEAP1) E3 ubiquitin ligase complex (PubMed:21196497).

Tissue Location

Widely expressed. Highest expression in adult muscle, kidney, lung, liver and in fetal muscle

NFE2L2 Antibody (S40) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Blocking Peptides](#)